Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.

By H. B. EL‐SERAG, K. Rudolph. Gastroenterology, 2007

5,012 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology, Oncology

View Paper: https://www.semanticscholar.org/paper/02c5864e3ba848b7b4db6a0f4a2c2fe73e92a3b1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. J. Llovet
2. Jordi Bruix1 , 2
3. M. Sherman
4. E. Brunt
5. V. Mazzaferro
6. E. Engels
7. Yujin Hoshida
8. R. Lopez

In Hepatology

1. J. Llovet
2. Jordi Bruix1 , 2
3. M. Sherman
4. V. Mazzaferro
5. Peter R. Galle
6. Lewis R. Roberts
7. E. Brunt
8. Yujin Hoshida

In Oncology

1. E. Engels
2. Jordi Bruix1 , 2
3. Sebastian M. B. Nijman
4. Guobin He
5. J. Goedert
6. R. Biggar
7. V. Mazzaferro
8. M. Karin

Citations in the corpus

• Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial , (2012, background): “In addition, the incidence of these etiologies varies among different patient populations [23,24].”
• MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. (2012, positive): “The male-to-female incidence ratio was 3.9:1 (Table 2), which recapitulates the observed HCC incidence in humans (29).”
• Cancer risk in people infected with human immunodeficiency virus in the United States (2008, background): “In the present study, we observed that liver cancer incidence rose over time, probably reflecting the effects of prolonged alcohol abuse or co-infection with hepatitis C or B viruses.(6,40)”
• Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. (2018, background): “It usually occurs in a background of chronic liver disease, 92 particularly in cirrhosis, which limits the feasibility of surgical resection.(2,3) Sorafenib, an oral multikinase 93 inhibitor, is the only systemic therapy that has been proven to extend overall survival when used as a 94 first-line tr”
• Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. (2017, background): “The most frequent risk factors of HCC comprise of alcohol intake, infection by hepatitis B (HBV) or hepatitis C (HCV) viruses, and metabolic syndrome.(2) Although surveillance protocols of patients at-risk to develop HCC have significantly improved, clinical outcome remains poor with a majority of p”